Polyclonal Rabbit anti‑Human TRAIL‑R3 / DCR1 Antibody (Biotin, aa32‑244, WB) LS‑C684100
Polyclonal Rabbit anti‑Human TRAIL‑R3 / DCR1 Antibody (Biotin, aa32‑244, WB) LS‑C684100
Antibody:
TRAIL-R3 / DCR1 Rabbit anti-Human Polyclonal (aa32-244) (Biotin) Antibody
Format:
Biotin, Unmodified
Overview
Antibody:
TRAIL-R3 / DCR1 Rabbit anti-Human Polyclonal (aa32-244) (Biotin) Antibody
Format:
Biotin, Unmodified
Specifications
Description
DCR1 antibody LS-C684100 is a biotin-conjugated rabbit polyclonal antibody to human DCR1 (TRAIL-R3) (aa32-244). Validated for WB.
Target
Human TRAIL-R3 / DCR1
Synonyms
TNFRSF10C | CD263 antigen | CD263 | Cytotoxic TRAIL receptor-3 | Decoy receptor 1 | DCR1 | DCR1-TNFR | LIT | Lymphocyte inhibitor of TRAIL | TRAIL-R3 | TRAILR3 | TRAIL receptor 3 | TRID
Reactivity
Human
(tested or 100% immunogen sequence identity)
Conjugations
Biotin.
Also available
Unconjugated or conjugated with
FITC,
Cy3,
HRP,
APC,
PE,
APC, Cy7.
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Immunogen
Recombinant TNFRSF10C (Glu32-Thr244)
Specificity
The antibody is a rabbit polyclonal antibody raised against TNFRSF10C.
Applications
- Western blot
- Applications tested for the base form of this product only
Presentation
PBS, pH 7.4, 0.02% Sodium Azide, 50% Glycerol
Storage
Avoid repeated freeze/thaw cycles. Store at 4°C for frequent use. Aliquot and store at -20°C for 12 months.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This antibody carries the LSBio 100% Guarantee.
LSBio Guarantee
Featured Products
Species:
Human
Applications:
Western blot
Species:
C. elegans
Applications:
ELISA
Species:
Human
Applications:
IHC, IHC - Paraffin, Western blot, Flow Cytometry
Reactivity:
Human
Range:
16.38-1600 pg/ml
Source:
E. coli
Tag:
His-GST
Request SDS/MSDS
To request an SDS/MSDS form for this product, please contact our Technical Support department at:
Technical.Support@LSBio.com
Requested From: United States
Date Requested: 11/25/2024